Corporate ActionAug 12, 2026, 04:05 PM
Outlook Therapeutics Commences Underwritten Public Offering
AI Summary
Outlook Therapeutics, Inc. announced the commencement of an underwritten public offering of its common stock and accompanying warrants. The company also intends to grant underwriters a 30-day option to purchase additional shares and/or warrants, up to 15% of the offering. Proceeds from the offering are intended to fund the commercial launch of LYTENAVA™ in the United States, as well as for working capital and general corporate purposes.
Key Highlights
- Commenced an underwritten public offering of common stock and accompanying warrants.
- Underwriters granted a 30-day option to purchase up to 15% additional securities.
- Net proceeds to support the commercial launch of LYTENAVA™ in the United States.
- Proceeds also allocated for working capital and general corporate purposes.
- Piper Sandler and BTIG are acting as joint bookrunning managers for the offering.
- Offering made pursuant to a Form S-3 shelf registration statement.
Price Impact
More from OTLK